

Lifecare Q4 2023 - Setting the stage

Redeye makes minor upwards adjustments to its fair value range following Lifecare's year-end report 2023. With a recently reinforced balance sheet the company stands before an eventful year ahead, which should include both automated production and launch of a veterinary product.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Lifecare Q4 2023 - Setting the stage](#)